Cargando…

Use tumor suppressor genes as biomarkers for diagnosis of non-small cell lung cancer

Lung cancer is the leading cause of death worldwide. Especially, non-small cell lung cancer (NSCLC) has higher mortality rate than the other cancers. The high mortality rate is partially due to lack of efficient biomarkers for detection, diagnosis and prognosis. To find high efficient biomarkers for...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Chuantao, Jiang, Man, Zhou, Na, Hou, Helei, Li, Tianjun, Yu, Hongsheng, Tan, Yuan-De, Zhang, Xiaochun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7881207/ https://www.ncbi.nlm.nih.gov/pubmed/33580150 http://dx.doi.org/10.1038/s41598-020-80735-x

Ejemplares similares

ALK rearrangements as mechanisms of acquired resistance to osimertinib in EGFR mutant non‐small cell lung cancer
por: Hou, Helei, et al.
Publicado: (2021)

Chemotherapy Alters the Phylogenetic Molecular Ecological Networks of Intestinal Microbial Communities
por: Cong, Jing, et al.
Publicado: (2019)

Anlotinib Combined with Toripalimab as Second-Line Therapy for Advanced, Relapsed Gastric or Gastroesophageal Junction Carcinoma
por: Jiang, Man, et al.
Publicado: (2022)

Discovery of targetable genetic alterations in advanced non-small cell lung cancer using a next-generation sequencing-based circulating tumor DNA assay
por: Hou, Helei, et al.
Publicado: (2017)

The efficacy and safety of apatinib for refractory malignancies: a review and meta-analysis
por: Sun, Dantong, et al.
Publicado: (2018)

Publisher Correction: Discovery of targetable genetic alterations in advanced non-small cell lung cancer using a next-generation sequencing-based circulating tumor DNA assay
por: Hou, Helei, et al.
Publicado: (2018)

Response to apatinib in chemotherapy-failed advanced spindle cell breast carcinoma
por: Zhou, Na, et al.
Publicado: (2016)

Concurrent TP53 mutations predict poor outcomes of EGFR-TKI treatments in Chinese patients with advanced NSCLC
por: Hou, Helei, et al.
Publicado: (2019)

Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis
por: Qin, Kang, et al.
Publicado: (2020)

Neoadjuvant PD-1 blockade plus chemotherapy versus chemotherapy alone in locally advanced stage II-III gastric cancer: A single-centre retrospective study
por: Zhang, Xuchen, et al.
Publicado: (2023)

Progress in the treatment of solid tumors with apatinib: a systematic review
por: Zhao, Deze, et al.
Publicado: (2018)

Survival-associated alternative splicing signatures in non-small cell lung cancer
por: Zhao, Deze, et al.
Publicado: (2020)

The role of MDM2 amplification and overexpression in therapeutic resistance of malignant tumors
por: Hou, Helei, et al.
Publicado: (2019)

The role of RICTOR amplification in targeted therapy and drug resistance
por: Zhao, Deze, et al.
Publicado: (2020)

MicroRNA-432 functions as a tumor suppressor gene through targeting E2F3 and AXL in lung adenocarcinoma
por: Chen, Ling, et al.
Publicado: (2016)

Targeted next generation sequencing in Chinese colorectal cancer patients guided anti-EGFR treatment and facilitated precision cancer medicine
por: Hou, Helei, et al.
Publicado: (2017)

Apatinib suppresses cell growth and metastasis and promotes antitumor activity of temozolomide in glioma
por: Wang, Chao, et al.
Publicado: (2018)

Glypican-5 is a tumor suppressor in non-small cell lung cancer cells
por: Guo, Lixia, et al.
Publicado: (2016)

Subunits of ARID1 serve as novel biomarkers for the sensitivity to immune checkpoint inhibitors and prognosis of advanced non-small cell lung cancer
por: Sun, Dantong, et al.
Publicado: (2020)

Role of YES1 amplification in EGFR mutation‐positive non‐small cell lung cancer: Primary resistance to afatinib in a patient
por: Tao, Junyan, et al.
Publicado: (2020)

The safety and serious adverse events of approved ALK inhibitors in malignancies: a meta-analysis
por: Hou, Helei, et al.
Publicado: (2019)

ARID1A deficiency associated with MMR deficiency and a high abundance of tumor-infiltrating lymphocytes predicts a good prognosis of endometrial carcinoma
por: Sun, Dantong, et al.
Publicado: (2023)

The Evaluation of Serum Biomarkers for Non-small Cell Lung Cancer (NSCLC) Diagnosis
por: Fang, Rui, et al.
Publicado: (2018)

Ezh2 Acts as a Tumor Suppressor in Kras-driven Lung Adenocarcinoma
por: Wang, Yanxiao, et al.
Publicado: (2017)

Tumor suppressor properties of the small C-terminal domain phosphatases in non-small cell lung cancer
por: Krasnov, George S., et al.
Publicado: (2019)

Small non-coding RNA biomarkers in sputum for lung cancer diagnosis
por: Su, Yun, et al.
Publicado: (2016)

Identification of a potential tumor suppressor gene, UBL3, in non-small cell lung cancer
por: Zhao, Xinchun, et al.
Publicado: (2020)

Long non-coding RNA LOC285194 functions as a tumor suppressor by targeting p53 in non-small cell lung cancer
por: Zhou, Huaping, et al.
Publicado: (2019)

Serum thrombospondin-2 is a candidate diagnosis biomarker for early non-small-cell lung cancer
por: Jiang, Yi-ming, et al.
Publicado: (2019)

Identification of serum MiRNAs as candidate biomarkers for non-small cell lung cancer diagnosis
por: Zhang, Xintong, et al.
Publicado: (2022)

Role of Dusp6 Phosphatase as a Tumor Suppressor in Non-Small Cell Lung Cancer
por: Moncho-Amor, Verónica, et al.
Publicado: (2019)

T cell exhaustion is associated with the risk of papillary thyroid carcinoma and can be a predictive and sensitive biomarker for diagnosis
por: Zhu, Chumeng, et al.
Publicado: (2021)

UNC5A, an epigenetically silenced gene, functions as a tumor suppressor in non-small cell lung cancer
por: Ding, Silu, et al.
Publicado: (2020)

miR-202 functions as a tumor suppressor in non-small cell lung cancer by targeting STAT3
por: Zhao, Zhonghai, et al.
Publicado: (2022)

P42 Ebp1 functions as a tumor suppressor in non-small cell lung cancer
por: Ko, Hyo Rim, et al.
Publicado: (2015)

miR-215 functions as a tumor suppressor and directly targets ZEB2 in human non-small cell lung cancer
por: HOU, YAN, et al.
Publicado: (2015)

miR-215 functions as a tumor suppressor and directly targets ZEB2 in human non-small cell lung cancer
por: Hou, Yan, et al.
Publicado: (2021)

Blood Tumor Mutational Burden as a Predictive Biomarker in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
por: Ma, Yuhui, et al.
Publicado: (2021)

MicroRNA‐based biomarkers for diagnosis of non‐small cell lung cancer (NSCLC)
por: Liao, Jipei, et al.
Publicado: (2020)

Cavity development: a potential biomarker for antiangiogenesis agents
por: Jiang, Man, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_upkk7nt9q27ttpc3d259e5ddu1